Mindewei

The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners.

Junshi hopes new scientist CEO can cure its woes

The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
1877.HK 688180.SHG

Past the Peak? Covid Drugs Frenzy Cools as Pandemic Eases

Simcere Pharmaceutical and Junshi Biosciences have gained marketing approvals for their Covid oral drugs, but the market reaction has been lukewarmKey Takeaways:The drugs Xiannuoxin and Mindewei have been conditionally approved…

Recent Articles

RELATED ARTICLES

  1. The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum lags the pace of leading rivals.
    Junshi narrows its losses but delivers no cure for share price woes
    1877.HK 688180.SHG
  2. Akeso marks profit milestone with swift rights issue
    9926.HK
  3. Test results for new cancer drug take Akeso investors on wild ride
    9926.HK
  4. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  5. Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
  6. Clinical trials come up short again for Alphamab Oncology
    9966.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva